Login to Your Account

FDA Unveils Plan for Structured Benefit-Risk Assessment

By Mari Serebrov
Washington Editor

Thursday, March 7, 2013
Seeking to lift the veil on its approval process, the FDA released a draft five-year plan describing the steps it's taking to further develop and implement a structured benefit-risk assessment to be used in agency reviews of drugs and biologics.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription